Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
First-in-class Transactivator-Free, Doxycycline-inducible... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
First-in-class Transactivator-Free, Doxycycline-inducible IL-18-engineered CAR-T cells for relapsed/refractory B-cell lymphomas
0
Authors
Pedro Justicia-Lirio
19 more
Pedro Justicia-Lirio
•
María Tristán‐Manzano
17 more
•
Francisco Martín
Published
August 15, 2024
Paper
Conversation
0
Reviews
0
Bounties
0
Sign in to review
Share your thoughts on this paper...
Best
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
Molecular Therapy — Nucleic Acids
Topics
Biology
Artificial Intelligence
Computer Science
Medicine
Cancer Oncology
Show all topics
DOI
10.1016/j.omtn.2024.102308
License
CC-BY-NC-ND
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
Molecular Therapy — Nucleic Acids
Topics
Biology
Artificial Intelligence
Computer Science
Medicine
Cancer Oncology
Show all topics
DOI
10.1016/j.omtn.2024.102308
License
CC-BY-NC-ND
